Fort Dodge Animal Health has launched PropoClear, a short-acting, intravenous general anaesthetic for dogs and cats.
The company believes that PropoClear, based on novel lipid-free micro-emulsion technology, will deliver significant clinical benefits over conventional lipid-based propofol emulsions, and will also deliver increased cost-effectiveness and convenience to practices.
PropoClear is indicated for use as a short-acting general anaesthetic for procedures lasting up to five minutes. It is also indicated for the induction and maintenance of general anaesthesia using incremental doses and for the induction of anaesthesia where maintenance is provided by inhalation.
According to Fort Dodge, PropoClear's unique lipid-free, nano-emulsion formulation and its inclusion of antimicrobial preservatives provide the following key benefits to practices:
Dr Jo Murrell, Department of Clinical Veterinary Science, Division of Companion Animals, the University of Bristol, said: "With currently available lipid-based propofol formulations unused drug should be discarded immediately once the vial has been opened leading to drug wastage or the potential for bacterial contamination of the remaining solution if this regulation is ignored. The new lipid-free propofol formulation, which also contains antimicrobial preservatives, overcomes this limitation and will provide significant clinical benefits in terms of the 28 day shelf life once broached."
Matthew Rowe, Marketing Manager for Companion Animals at Fort Dodge, said: "In developing PropoClear, it was our goal to deliver an anaesthetic product with the same proven efficacy as the existing solution but which offered significant benefits in terms of enhanced safety, cost and convenience.
"PropoClear contains the same concentration of the established active molecule and follows familiar guide dose protocols to ensure ease of use. We have been encouraged by the positive feedback received during product trials and believe the significant advantages its offers, both clinically and financially, to practices in challenging times, will ensure its rapid adoption by veterinary practices across the UK."
Fort Dodge Animal Health has announced that its Duvaxyn WNV vaccine against West Nile Virus (WNV) is now available in the UK, following its licensing through the European Medicines Agency (EMEA).
Duvaxyn WNV is the first vaccine available in Europe to protect horses against this emerging disease threat. 288 horses and two people in Italy were found to be infected with WNV during the outbreak that hit northern Italy in late 2008 where it is now considered endemic. The disease is endemic in all areas of North America where it has claimed the lives of both horses and humans.
West Nile Virus is caused by a highly contagious flavivirus, which is transmitted by mosquitoes, primarily of the Culex species. The natural hosts of West Nile virus are birds, with migratory birds from Africa carrying the disease. Mosquitoes become infected after taking a blood meal from infected birds and then may transmit the disease to horses and even humans. While horses are 'dead end hosts,' the consequences can be severe as the virus causes encephalitis or meningitis. Mortality rates among horses which develop neurological signs are high and there is no palliative cure for the disease. Treatment is limited to symptomatic relief which can be long and expensive.
Sabrina Jordan, UK Business Manager for Equine Vaccines at Fort Dodge said: "WNV is an increasing threat to the equestrian sector in the UK and is a particular challenge for owners who transport their horses around the world.
"The fact that a vaccine is now available will undoubtedly offer peace of mind to the equestrian community. They can be reassured that horses in the UK can now be vaccinated against WNV with a vaccine that has already been shown to be highly effective in protecting horses in America.
"With any vaccine, a record that a horse has been vaccinated with Duvaxyn WNV should be recorded in its horse passport. By presenting this vaccine in pre-filled syringes with Infovax-ID labels, we've aimed to make both the administration and record keeping of Duvaxyn WNV as convenient as possible.
"To build understanding of this potentially fatal disease threat, we are continuing to work with governments and authorities at a national and European level, as well as working in partnership with the UK's veterinary community to ensure that owners are fully informed about the risk WNV poses and of the benefits of vaccination."
Fort Dodge Animal Health has announced that its Zulvac 8 Ovis® Bluetongue sheep vaccine is now licensed and available in the UK. The company believes that the product will provide significant benefits to sheep farmers.
Zulvac 8 Ovis® is an inactivated adjuvanted vaccine for the active immunisation of sheep by subcutaneous injection against Bluetongue Serotype 8. It also provides a reduction in viraemia. Administration is a two x 2 ml dose primary course in year one but only a single shot booster in the second year.
The use of Zulvac 8 Ovis as a booster for animals previously vaccinated with a primary course from other manufacturers is in line with Defra (2009) guidance: 'No problems are anticipated with re-vaccinating animals which have already received a primary course of vaccination with a different vaccine 1'.
The first dose can be administered from one month of age and Zulvac 8 Ovis® is proven for use in pregnant sheep. The onset of immunity is provided 25 days after the second dose.
Fort Dodge says Zulvac provides cost savings to farmers through its pricing strategy. While the price for the two dose primary course is competitive with alternative vaccines, for animals which were vaccinated last year and require only a single shot booster, the cost will be half that of competitive offerings, providing a significant incentive to farmers to vaccinate.
The vaccine is supported by a specific Zulvac Ovis fixed 2ml dose applicator with Sterimatic needle protector and cleaning system which aids administration and hygiene and is sold separately.
David Bartram MRCVS, Veterinary Technical Manager at Fort Dodge, said: "Sheep farmers have been waiting for a Bluetongue vaccine which offers a cost effective solution to vaccination - particularly for animals which received their primary course last year and are simply in need of a booster. We expect the fact that it's licensed for use in pregnant sheep to also prove attractive.
"Zulvac 8 Ovis® is the latest addition to Fort Dodge's Zulvac range for both cows and sheep. It is already used in Europe and has helped protect millions of animals."
Fort Dodge Animal Health has announced that the European Medicines Agency (EMEA) has approved a new label claim for ProMeris Duo® for dogs. The new claim extends protection offered by ProMeris Duo to include "treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs".
Accoding to the company, dealing with demodectic mange on a dog has in the past been time-consuming for the pet owner and sometimes required vets to use a product off-label. Despite available measures, some dogs fail to respond to treatment and even require euthanasia due to the severity of the condition.
Rami Cobb, BVSc (Hons), MACVSc, Senior Vice President of Pharmaceutical Research and Development at Fort Dodge Animal Health said: "With the addition of the demodectic mange claim to the ProMeris Duo label, vets have the option of using the recognized efficacy of amitraz in a convenient spot-on formulation to treat and control this condition.
"When we conducted field studies for the label claim, the before and after pictures of the dogs treated with ProMeris Duo were remarkable. Visible improvements in the dog's condition were seen following the first treatment and in most cases, demodex mites could not be found after just a few months."
ProMeris Duo was evaluated for efficacy against demodectic mange mites in naturally infected dogs. Study results indicated dogs treated monthly with ProMeris Duo showed significant reduction in mite numbers and improvement in clinical signs after three months.
ProMeris Duo is now licensed for the following indications: For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), as well as ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
A new long acting sheep injection has been launched by Fort Dodge Animal Health which the company says will offer significant benefits to sheep farmers for both internal and external parasite control.
Cydectin 2% LA for sheep is the latest product to join the Cydectin range and follows the long acting injection for cattle.
Based on Moxidectin, the product delivers a long action against worms, up to 111 days and scab, 60 days from a single injection.
Andrew Wylie from Fort Dodge said: "To put this into context, apart from the existing Cydectin range which lasts up to 35 days, no other product is licensed with persistent activity against worms and scab. Cydectin 2% LA for sheep offers three times the worm cover and double the scab cover from a single injection.
"Therefore farmers will benefit from Cydectin 2% LA through the combination of a single injection with extended persistency leading to a reduction in the number of treatments needed for worms and scab and the potential increase in lamb weight gain due to a lower worm and scab challenge."
Fort Dodge recommends the following three key uses for Cydectin 2% LA given the persistent effect and single shot:
Administration is by a single sub-cutaneous injection high up the neck at the base of the ear which is designed to limit the withhold period to 104 days. The technique is not difficult and, if used with the multidose applicator supplied, farmers will find it a straightforward procedure.
Cydectin 2% LA is available in 50ml, 200ml and 500ml bottles and with a dose rate of 1ml per 20kg, a 500ml pack will treat 200 sheep at 50kg. For further, call Fort Dodge on 01489 781711.
Fort Dodge Animal Health has announced it is working with the authorities to put measures in place to make its West Nile Virus vaccine, licensed in the United States, available to the European equine market. These measures will ensure a vaccine is readily available in the event of an outbreak in the UK.
This news comes as the Zooprophylactic Institute of Teramo, the Italian National Reference Centre for Exotic Diseases, has confirmed an outbreak of WNV among horses in stables in the northern province of Ferrara. About 20 horses are believed to have been affected.
Fort Dodge was the first company to develop and fully license a vaccine to protect horses against this potentially deadly disease. An inactivated whole virus vaccine, it was the only vaccine available in the United States at the height of the 2002 outbreak, which affected 15,000 horses. The U.S. Department of Agriculture credited the vaccine with contributing to the 70 per cent decline in U.S. equine West Nile cases since the height of the outbreak. WNV is now considered endemic in all areas of North America.
"As this latest outbreak of WNV in Italy highlights, the disease presents an increasing threat to the equestrian sector in Europe," says Helen Barnes, EMEA Equine Business Manager for Fort Dodge. "With little current natural immunity among the equine population, the consequences of a major outbreak could be devastating."
"Until now, horse owners in Europe have perhaps believed WNV is not a disease they should be concerned with but the outbreak in Ferrara came out of the blue, and at a time when a human case of WNV was also reported in the same province. This situation of both human and equine cases being reported is identical to that seen in the outbreaks in the United States. It's a stark reminder of the challenge this disease poses, particularly as environmental factors, such as global warming and heavy rains threaten to create mass breeding grounds for mosquitoes," says Barnes.
"Our experience with WNV in the United States has given us an exceptional understanding of the disease and the importance of vaccination. We now look forward to working in partnership with the European governments, the EU Commission and the veterinary community across Europe to help build understanding and knowledge of this dangerous emerging disease threat."
Fort Dodge Animal Health has launched the UK’s first free diagnostics service to assist vets in diagnosing Lyme disease in dogs.
The introduction of the new Lyme Disease Surveillance Service (LDSS) reflects concerns that the increasing incidence of the disease in humans could be followed by a similar increase in dogs.
Canine Lyme disease, while still rare in the UK, is known to be difficult to diagnose with vague symptoms and a variety of clinical presentations.
Infest-Nation, the ProMeris Parasite Report launched in late 2007 and based on interviews with 2,000 vets and pet owners, cited figures from the Health Protection Agency (HPA) which reported 768 cases of human Lyme disease in 2006, an increase of 263% since 2003. The increase in human incidence is believed to be attributable to an increase in the human population, better diagnosis and more favourable climatic conditions for ticks as the vector for the disease.
According to Fort Dodge, it’s possible that the increase in Lyme disease in humans will be mirrored in the canine population. Forty per cent of vets contacted for Infest-Nation had reported a significant rise in the tick problem over the last five years and 75% of dog owners didn’t know how to check their dogs for parasites and didn’t treat them as frequently as the recommended once a month.
Participation in the LDSS is free for veterinary practices registering with the scheme. You can do this by contacting Fort Dodge on 01489 781711 or by email at fortdodgeuk@fdah.com. You will then be provided with testing kits and full instructions on the submission of blood samples.
Animal health specialist Fort Dodge Animal Health has announced the appointment of David Bartram BVetMed MRCVS DipM MCIM CDipAF as Technical Services Manager for Large Animals. David rejoins Fort Dodge after eight years, having previously been a Business Unit Manager for its Cydectin business. David Bartram graduated from the Royal Veterinary College in London in 1988 and, after three years in large animal practice, moved into the pharmaceutical industry where he has worked for the last 16 years. His most recent role was at Lilly, where he worked in Finance in the human sector of its pharmaceutical business. David has post graduate qualifications in marketing and finance. He replaces Susan Corning who has moved to a new role with Fort Dodge in Italy.
A new Support Services Guide has been launched by Fort Dodge Animal Health, designed as an aid to the company’s Practice Support Programme. The guide has been designed to provide a comprehensive reference on all the services Fort Dodge offers its practice customers. These include a comprehensive range of client materials, such as pet healthcare records, reminder stationery and pet health information leaflets, as well as various business support initiatives such as the well-respected Fort Dodge (FDI) bench-marking facility, a vaccine amnesty package and Practice PR. This press relations service provided via a professional PR agency has assisted a number of practices with local publicity, helping them increase their visibility in the local community.
Practices wishing to obtain a copy of the new guide should contact Fort Dodge on 01489 774249.